KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to 38.56%.

  • Vertex Pharmaceuticals' EBIT Margin fell 17100.0% to 38.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.06%, marking a year-over-year increase of 366100.0%. This contributed to the annual value of 2.11% for FY2024, which is 409400.0% down from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' EBIT Margin stood at 38.56%, which was down 17100.0% from 38.83% recorded in Q2 2025.
  • Vertex Pharmaceuticals' EBIT Margin's 5-year high stood at 53.15% during Q3 2021, with a 5-year trough of 132.85% in Q2 2024.
  • Its 5-year average for EBIT Margin is 30.43%, with a median of 41.17% in 2023.
  • Per our database at Business Quant, Vertex Pharmaceuticals' EBIT Margin crashed by -1740200bps in 2024 and then soared by 1716800bps in 2025.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' EBIT Margin stood at 42.35% in 2021, then rose by 6bps to 44.88% in 2022, then decreased by -13bps to 39.26% in 2023, then dropped by -10bps to 35.23% in 2024, then rose by 9bps to 38.56% in 2025.
  • Its EBIT Margin was 38.56% in Q3 2025, compared to 38.83% in Q2 2025 and 22.75% in Q1 2025.